The primary objective of the Immune Analysis Core is to establish standardized assays of cellular and humoral immune responses for the immunotherapeutic approaches being developed and tested in Individual Research Projects 1, 2 and 3 of the RPCI Ovarian Cancer SPORE. It will be also be responsible for enumerating and characterizing myeloid derived suppressor cells (MDSCs) by flow cytometry for Research Projects 4. The Core will routinely provide Ovarian Cancer SPORE investigators with high quality, state-of-the- art flow cytometry, cellular monitoring by ELISPOT, proliferation and cytotoxicity assays, and multiplex cytokine bead array.
The specific aims of the Immune Analysis Core are to: 1) Provide cell banking services for immune monitoring assays requiring viable mononuclear cells. 2) Provide state-of-the-art, multi-color, fluorescence activated cell sorting and analytical support for Individual Research Projects, Career Development and Developmental Research Projects. This includes high-speed sorting and multi-color analysis of cellular subsets. 3) Provide state-of-the-art ELISPOT, ELISA, proliferation and cytotoxicity assays for the functional characterization of antigen-specific T cell responses. 4) Provide state-of-the-art patient sample handling and assessment of immune responses, with standardized SOPs, quality assurance, quality control and data management practices to monitor assay performance and validate data quality. In addition to these established immunoassays services, the Immune Analysis Core will be instrumental in developing new methodologies and making them available to the SPORE investigators. It also has a significant educational role, working with all SPORE investigators including PI's, technicians and young investigators on their assay development, proper use of instrumentation and interpretation of their data.
Centralization and standardization of the performance of the immunoassays will facilitate head-to-head comparisons of the immunological therapies being tested using the same outcome measures and provide for more efficient use of the SPORE's resources.
|Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320|
|Wang, Zehua; Yang, Bo; Zhang, Min et al. (2018) lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell 33:706-720.e9|
|Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035|
|Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182|
|Shenoy, Gautam N; Loyall, Jenni; Berenson, Charles S et al. (2018) Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments. J Immunol 201:3750-3758|
|Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430|
|Wang, Yue; Wang, Zehua; Xu, Jieni et al. (2018) Systematic identification of non-coding pharmacogenomic landscape in cancer. Nat Commun 9:3192|
|Minlikeeva, Albina N; Moysich, Kirsten B; Mayor, Paul C et al. (2018) Anthropometric characteristics and ovarian cancer risk and survival. Cancer Causes Control 29:201-212|
|Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472|
|Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33|
Showing the most recent 10 out of 128 publications